Identification of LMX1B as a novel oncogene in human ovarian cancer

Oncogene

Volumn 33, Issue 33, 2014, Pages 4226-4235

  He, L ^a,b   Guo, L ^a   Vathipadiekal, V ^a,b   Sergent, P A ^a   Growdon, W B ^a,b   Engler, D A ^c   Rueda, B R ^a,b   Birrer, M J ^a,b   Orsulic, S ^d   Mohapatra, G ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

aCGH; LMX1B; ovarian cancer; transcription factor; tumor progression

Indexed keywords

BRCA1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIM HOMEODOMAIN-CONTAINING TRANSCRIPTION FACTOR 1B; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CARCINOGENESIS; CELL CULTURE; CELL MIGRATION; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIM HOMEODOMAIN CONTAINING TRANSCRIPTION FACTOR 1B GENE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR XENOGRAFT;

MUS MUSCULUS;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; FEMALE; GENE AMPLIFICATION; HUMANS; LIM-HOMEODOMAIN PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TUMOR BURDEN;

EID: 84906223358     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.375     Document Type: Article

References (49)

1. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.
3. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ et al. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5: 19-24. (Pubitemid 38121593)
4. Pinkel D, Albertson DG. Array comparative genomic hybridization and its applications in cancer. Nat Genet 2005; 37(Suppl): S11-S17. (Pubitemid 40770398)
5. Fishman A, Shalom-Paz E, Fejgin M, Gaber E, Altaras M, Amiel A. Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization. Int J Gynecol Cancer 2005; 15: 261-266. (Pubitemid 40396962)
6. Israeli O, Gotlieb WH, Friedman E, Korach J, Friedman E, Goldman B et al. Genomic analyses of primary and metastatic serous epithelial ovarian cancer. Cancer Genet Cytogenet 2004; 154: 16-21. (Pubitemid 39286167)
7. Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, Lohrs U et al. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 2006; 126: 101-109. (Pubitemid 44025077)
8. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004; 10: 1251-1256. (Pubitemid 39540444)
9. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007; 67: 3074-3084. (Pubitemid 46724844)
10. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183. (Pubitemid 38337497)
11. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006; 125: 1269-1281. (Pubitemid 43949521)
12. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 1253-1267. (Pubitemid 43929093)
13. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002; 1: 53-62. (Pubitemid 41039176)
14. Xing D, Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci USA 2005; 102: 6936-6941. (Pubitemid 40675420)
15. Xing D, Orsulic S. A mouse model for the molecular characterization of brca1- associated ovarian carcinoma. Cancer Res 2006; 66: 8949-8953. (Pubitemid 44521109)
16. Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell 2013; 152: 1237-1251.
17. Miao J, Wang Z, Provencher H, Muir B, Dahiya S, Carney E et al. HOXB13 promotes ovarian cancer progression. Proc Natl Acad Sci USA 2007; 104: 17093-17098. (Pubitemid 350210997)
18. McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL et al. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One 2011; 6: e28077.
19. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T et al. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol 2013; 128: 506-511.
20. Burbach JP, Smits S, Smidt MP. Transcription factors in the development of midbrain dopamine neurons. Ann NY Acad Sci 2003; 991: 61-68. (Pubitemid 36793801)
21. Guo C, Qiu HY, Huang Y, Chen H, Yang RQ, Chen SD et al. Lmx1b is essential for Fgf8 and Wnt1 expression in the isthmic organizer during tectum and cerebellum development in mice. Development 2007; 134: 317-325.
22. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
23. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418-425. (Pubitemid 34326692)
24. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 2007; 104: 10069-10074. (Pubitemid 47175264)
25. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010; 107: 15449-15454.
26. Dreyer SD, Zhou G, Baldini A, Winterpacht A, Zabel B, Cole W et al. Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet 1998; 19: 47-50. (Pubitemid 28242021)
27. Chen H, Lun Y, Ovchinnikov D, Kokubo H, Oberg KC, Pepicelli CV et al. Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella syndrome. Nat Genet 1998; 19: 51-55. (Pubitemid 28242022)
28. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 2009; 16: 521-532.
29. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res 2010; 70: 4005-4014.
30. Bach I. The LIM domain: regulation by association. Mech Dev 2000; 91: 5-17. (Pubitemid 30125900)
31. Hunter CS, Rhodes SJ. LIM-homeodomain genes in mammalian development and human disease. Mol Biol Rep 2005; 32: 67-77. (Pubitemid 40875253)
32. Gehring WJ, Affolter M, Burglin T. Homeodomain proteins. Annu Rev Biochem. 1994; 63: 487-526. (Pubitemid 24218641)
33. McIntosh I, Dunston JA, Liu L, Hoover-Fong JE, Sweeney E. Nail patella syndrome revisited:50 years after linkage. Ann Hum Genet 2005; 69(Pt 4): 349-363. (Pubitemid 40990558)
34. Bongers EM, Gubler MC, Knoers NV. Nail-patella syndrome. Overview on clinical and molecular findings. Pediatr Nephrol 2002; 17: 703-712.
35. Sato U, Kitanaka S, Sekine T, Takahashi S, Ashida A, Igarashi T. Functional characterization of LMX1B mutations associated with nail-patella syndrome. Pediatr Res 2005; 57: 783-788. (Pubitemid 40727106)
36. White KL, Rider DN, Kalli KR, Knutson KL, Jarvik GP, Goode EL. Genomics of the NFkappaB signaling pathway: hypothesized role in ovarian cancer. Cancer Causes Control 2011; 22: 785-801.
37. Johnson JD, Zhang W, Rudnick A, Rutter WJ, German MS. Transcriptional synergy between LIM-homeodomain proteins and basic helix-loop-helix proteins: the LIM2 domain determines specificity. Mol Cell Biol 1997; 17: 3488-3496. (Pubitemid 27281825)
38. Rascle A, Neumann T, Raschta AS, Neumann A, Heining E, Kastner J et al. The LIMhomeodomain transcription factor LMX1B regulates expression of NF-kappa B target genes. Exp Cell Res 2009; 315: 76-96.
39. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
40. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
41. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11-19.
42. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436. (Pubitemid 44050137)
43. Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancerrelated inflammation. Ann Med 2010; 42: 161-170.
44. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J et al. Stanniocalcin 1. and ovarian tumorigenesis. J Natl Cancer Inst 2010; 102: 812-827.
45. Pressman CL, Chen H, Johnson RL. LMX1B, a LIM homeodomain class transcription factor, is necessary for normal development of multiple tissues in the anterior segment of the murine eye. Genesis 2000; 26: 15-25. (Pubitemid 30123462)
46. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011; 331: 1553-1558.
47. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A et al. A genetically defined model for human ovarian cancer. Cancer Res 2004; 64: 1655-1663. (Pubitemid 38428686)
48. Gabeau-Lacet D, Engler D, Gupta S, Scangas GA, Betensky RA, Barker II FG et al. Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. J Neuropathol Exp Neurol 2009; 68: 1155-1165.
49. Mohapatra G, Kim DH, Feuerstein BG. Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosomes Cancer 1995; 13: 86-93.